Keuangan Eli Lilly and Company (LLY)
NYSE · Healthcare · Drug Manufacturers - General · Karyawan: 50.000 · CEO: David A. Ricks
- Harga
- $1.417,54 +3,19%
- Kapitalisasi pasar
- $1,33 T
- Nilai perusahaan
- $1,38 T
- Laporan terakhir
- Q3 '26 diajukan 2026-10-29
- Laporan berikutnya
- 2027-02-03 Estimasi EPS: $11,07
Pendapatan (TTM)$86,5 M+45,5% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)46,1%+1,7 poin vs tahun laluLaba operasional: $39,8 M
Laba bersih (TTM)$27,6 M+49,8% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)$19,7 M+118,0% vs tahun laluCapex: $11 M
EPS dilusian (TTM)$30,81+50,7% vs tahun laluJumlah 4 kuartal terakhir
Kas neto-$44,6 M-36,9% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $1,33 T EV $1,38 T
- Pendapatan
- $86,5 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +39% Konsensus FY2026
- Margin laba
- 31,9% Laba bersih / pendapatan, TTM
- P/E
- 45,9× Forward 40,3× (FY2026)
- P/S
- 15,4× Harga / penjualan, TTM
- EV / EBITDA
- 30,8× TTM
- Arus kas bebas
- $19,7 M 12 bulan terakhir
- Laba bersih
- $27,6 M 12 bulan terakhir
- Estimasi pendapatan
- $90,4 M Konsensus FY2026
- Laba
- 2027-02-03 Estimasi pendapatan: $24,4 M
- Dividen
- $6,69 Per saham, 12 bulan terakhir
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-10-29): pendapatan melampaui 8,0%, EPS melampaui 31,0%Pendapatan $24,4 M vs $22,6 M yang diharapkan (+8,0%); EPS $7,48 vs $5,71 (+31,0%).
- Pertumbuhan pendapatan melambat: 38,6% yoyPendapatan Q3 '26: $24,4 M, rata-rata empat kuartal sebelumnya: 49,9%.
- Margin operasional 46,1% (TTM), dibanding tahun lalu: +1,7 poinLaba operasional tumbuh 50,9%, pendapatan tumbuh 45,5%.
- 14,6% dari laba sebelum pajak tergerus kerugian non-operasionalLaba sebelum pajak $34,8 M vs laba operasional $39,8 M (TTM). Kerugian dari kepemilikan saham dan pos sekali-pakai lainnya menekan laba bersih dan EPS - laba operasional adalah ukuran bisnis yang lebih bersih.
- Capex: 12,7% dari pendapatan (tahun lalu 11,9%)$11 M diinvestasikan dalam 4 kuartal terakhir (+56,0% dibanding tahun sebelumnya). Arus kas bebas: $19,7 M = 71,3% dari laba bersih.
- $11,8 M dikembalikan ke pemegang saham = 60,1% dari arus kas bebasBuyback: $5,84 M (tahun lalu $4,65 M), dividen: $5,98 M, kompensasi saham: $698 jt (TTM).
- Jumlah saham dilusian turun dalam setahun: 0,6%Saham dilusian pada Q3 '26: 893 jt, setahun sebelumnya: 899 jt.
- Utang neto: $44,6 MKas + investasi jangka pendek: $4,89 M, utang termasuk sewa: $49,5 M; tahun lalu utang neto: $32,6 M.
Kuartal terakhir: Q3 '26
Kuartal berakhir 2026-09-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q3 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $24,4 M | $17,6 M | +38,6% |
| Margin kotor | 83,9% | 82,9% | +1,0 poin |
| Laba operasional | $8,61 M | $8,39 M | +2,6% |
| Margin operasional | 35,3% | 47,6% | -12,4 poin |
| Laba bersih | $6,45 M | $5,58 M | +15,6% |
| EPS dilusian | $7,22 | $6,21 | +16,3% |
| Arus kas operasional | $11,4 M | $8,84 M | +29,0% |
| Capex | $3,18 M | $224 jt | +1.319,4% |
| Arus kas bebas | $8,22 M | $8,61 M | -4,6% |
| R&D | $4,25 M | $3,47 M | +22,5% |
| Kompensasi berbasis saham | $200 jt | $151 jt | +32,4% |
Dilaporkan vs konsensus
2026-10-29| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $24,4 M | $22,6 M | +8,0% |
| EPS (basis konsensus) | $7,48 | $5,71 | +31,0% |
Dari laporan 2026-10-29 untuk Q3 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q3 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Cardiometabolic Health | $19,8 M | +50,0% | 81,5% | – | – | |
| Oncology | $2,6 M | +8,0% | 10,7% | – | – | |
| Neuroscience | $444 jt | +40,6% | 1,8% | – | – | |
| Immunology | $1,44 M | +5,3% | 5,9% | – | – | |
| Other Product, Total | – | – | – | – | – |
Pendapatan per wilayah
porsi dari total| Segmen | Q3 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| United States | $15,1 M | +33,9% | 62,0% | $54,5 M | +37,6% | |
| Non-US | $3,21 M | +90,0% | 13,1% | $18,7 M | +279,7% | |
| Europe | $4,46 M | +27,5% | 18,3% | $15,3 M | +40,4% | |
| CHINA | $947 jt | +69,0% | 3,9% | $3,05 M | +60,3% | |
| JAPAN | $648 jt | +16,8% | 2,7% | $2,5 M | +22,8% |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- $30,6 M
- Capex
- -$11 M
- Buyback
- -$5,84 M
- Dividen
- -$5,98 M
- Akuisisi
- -$10,8 M
- Utang neto diterbitkan
- $7,32 M
- Kompensasi berbasis saham
- $698 jt
- Arus kas bebas
- $19,7 M
- Dikembalikan ke pemegang saham / FCF
- 60,1%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | 45,9× | 63,0× | 46,6× – 100,0× |
| EV / EBITDA | 30,8× | 42,0× | 31,6× – 63,8× |
| EV / Penjualan | 15,9× | 14,0× | 9,8× – 16,1× |
| Harga / FCF | 67,8× | 104,2× 4 dari 5 tahun | 48,9× – 184,9× |
| Harga / Nilai buku | 31,4× | 39,2× | 29,3× – 49,0× |
| Imbal hasil FCF | 1,5% | 0,8% | -0,6% – 2,0% |
| Imbal hasil modal yang diinvestasikan | 30,5% | 23,9% | 19,8% – 30,2% |
| Imbal hasil ekuitas | 83,6% | 64,4% | 48,6% – 77,8% |
Analis
Target konsensus $1.433,72 (+1,1%)
rentang $940,00 – $1.650,00 · peringkat Buy
Beli kuat0
Beli34
Tahan9
Jual3
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $90,4 M | +38,7% | $35,15 | +53,2% | 40,3× | 12 |
| FY2027 | $105 M | +16,4% | $49,36 | +40,4% | 28,7× | 15 |
| FY2028 | $118 M | +11,8% | $56,62 | +14,7% | 25,0× | 9 |
| FY2029 | $128 M | +8,7% | $64,50 | +13,9% | 22,0× | 3 |
| FY2030 | $138 M | +8,2% | $71,19 | +10,4% | 19,9× | 3 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 197 angka yang ditandai Eli Lilly and Company dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $5,79 M | $4,26 M | +35,9% | $5,38 M | $3,23 M | +66,6% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $22,1 M | $16,1 M | +37,1% | $17,8 M | $11 M | +61,4% |
| Accounts Receivable, Allowance for Credit Loss, Current | $21,7 jt2025-09-30 | $15,7 jt | +38,2% | $14,9 jt2024-12-31 | $14,8 jt | +0,7% |
| Accrued Income Taxes, Noncurrent | $6,07 M | $6,29 M | -3,6% | $5,88 M | $4,06 M | +44,7% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $13,4 M | $12,4 M | +7,8% | $12,6 M | $11,8 M | +6,5% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$2,63 M | -$3,21 M | +18,0% | -$2,88 M | -$4,32 M | +33,4% |
| Additional Paid in Capital, Common Stock | $7,31 M | $7,23 M | +1,1% | $7,35 M | $7,44 M | -1,3% |
| Advertising Expense | – | – | – | $2,9 M | $1,4 M | +107,1% |
| Amortization of Intangible Assets | – | – | – | $488 jt | $553 jt | -11,8% |
| Assets | $148 M | $115 M | +28,8% | $112 M | $78,7 M | +42,9% |
| Assets, Current | $65,3 M | $62,1 M | +5,1% | $55,6 M | $32,7 M | +69,9% |
| Cash and Cash Equivalents, at Carrying Value | $4,89 M | $9,79 M | -50,1% | $7,27 M | $3,27 M | +122,4% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $4,89 M | $9,79 M | -50,1% | $7,27 M | $3,27 M | +122,4% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$4,07 M | $6,42 M | -163,4% | $4 M | $449 jt | +790,9% |
| Commercial Paper | $02025-12-31 | $4,34 M | -100,0% | $0 | $4,34 M | -100,0% |
| Common Stock, Dividends, Per Share, Declared | $0,00 | $0,00 | – | $6,23 | $5,40 | +15,4% |
| Common Stock, Shares Authorized | 3,2 M2025-12-31 | 3,2 M | 0,0% | 3,2 M | 3,2 M | 0,0% |
| Common Stock, Shares Held in Employee Trust | $3,01 M | $3,01 M | 0,0% | $3,01 M | $3,01 M | 0,0% |
| Common Stock, Shares Held in Employee Trust, Shares | 50 jt2025-12-31 | 50 jt | 0,0% | 50 jt | 50 jt | 0,0% |
| Common Stock, Shares, Issued | 945 jt2025-12-31 | 948 jt | -0,3% | 945 jt | 948 jt | -0,3% |
| Common Stock, Value, Issued | $588 jt | $591 jt | -0,6% | $590 jt | $592 jt | -0,3% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $6,58 M | $6,09 M | +8,0% | $22,1 M | $10,6 M | +108,4% |
| Cost of Goods and Services Sold | $3,93 M | $3,01 M | +30,8% | $11,1 M | $8,42 M | +31,3% |
| Current Federal Tax Expense (Benefit) | – | – | – | $4,64 M | $3,34 M | +38,8% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $2,16 M | $1,43 M | +51,0% |
| Current Income Tax Expense (Benefit) | – | – | – | $6,8 M | $4,77 M | +42,4% |
| Debt Securities, Available-for-sale | $356 jt2025-09-30 | $685 jt | -48,0% | $669 jt2024-12-31 | $657 jt | +1,8% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $3,3 jt2025-09-30 | $7,2 jt | -54,2% | $1,6 jt2024-12-31 | $3,4 jt | -52,9% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $11,1 jt2025-09-30 | $29,2 jt | -62,0% | $43,2 jt2024-12-31 | $37,9 jt | +14,0% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 | $160 jt2025-09-30 | $293 jt | -45,4% | $255 jt2024-12-31 | $247 jt | +3,2% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | $63,8 jt2025-09-30 | $101 jt | -36,7% | $93,3 jt2024-12-31 | $98,4 jt | -5,2% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $119 jt2025-09-30 | $185 jt | -35,5% | $226 jt2024-12-31 | $228 jt | -1,1% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $12,7 jt2025-09-30 | $106 jt | -88,0% | $95,2 jt2024-12-31 | $84,1 jt | +13,2% |
| Debt Securities, Available-for-sale, Unrealized Loss Position | $177 jt2025-09-30 | $368 jt | -51,8% | $491 jt2024-12-31 | $452 jt | +8,7% |
| Debt, Current | $2,52 M | $1,63 M | +54,1% | $1,64 M | $5,12 M | -68,0% |
| Debt, Long-term and Short-term, Combined Amount | $42,5 M2025-12-31 | $33,6 M | +26,3% | $42,5 M | $33,6 M | +26,3% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | -$1,15 M | -$2,21 M | +48,0% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$558 jt | -$473 jt | -18,0% |
| Deferred Income Tax Assets, Net | $11 M | $8,96 M | +22,2% | $9,96 M | $8 M | +24,5% |
| Deferred Income Tax Expense (Benefit) | – | – | – | -$1,71 M | -$2,68 M | +36,4% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $1,72 M2025-12-31 | $1,78 M | -3,4% | $1,72 M | $1,78 M | -3,4% |
| Deferred Tax Assets, Gross | $15,6 M2025-12-31 | $12,4 M | +25,6% | $15,6 M | $12,4 M | +25,6% |
| Deferred Tax Assets, in Process Research and Development | $4,52 M2025-12-31 | $4,6 M | -1,8% | $4,52 M | $4,6 M | -1,8% |
| Deferred Tax Assets, Inventory | $711 jt2025-12-31 | $0 | – | $711 jt | $0 | – |
| Deferred Tax Assets, Net | $9,84 M2025-12-31 | $7,93 M | +24,1% | $9,84 M | $7,93 M | +24,1% |
| Deferred Tax Assets, Net of Valuation Allowance | $14,4 M2025-12-31 | $11,5 M | +25,5% | $14,4 M | $11,5 M | +25,5% |
| Deferred Tax Assets, Operating Loss Carryforwards | $911 jt2025-12-31 | $587 jt | +55,2% | $911 jt | $587 jt | +55,2% |
| Deferred Tax Assets, Other | $1 M2025-12-31 | $599 jt | +67,6% | $1 M | $599 jt | +67,6% |
| Deferred Tax Assets, Tax Credit Carryforwards | $649 jt2025-12-31 | $577 jt | +12,5% | $649 jt | $577 jt | +12,5% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | $556 jt2025-12-31 | $565 jt | -1,6% | $556 jt | $565 jt | -1,6% |
| Deferred Tax Assets, Valuation Allowance | $1,22 M2025-12-31 | $964 jt | +26,9% | $1,22 M | $964 jt | +26,9% |
| Deferred Tax Liabilities, Goodwill and Intangible Assets | $1,26 M2025-12-31 | $1,18 M | +7,0% | $1,26 M | $1,18 M | +7,0% |
| Deferred Tax Liabilities, Gross | $4,54 M2025-12-31 | $3,53 M | +28,7% | $4,54 M | $3,53 M | +28,7% |
| Deferred Tax Liabilities, Other | $381 jt2025-12-31 | $414 jt | -8,0% | $381 jt | $414 jt | -8,0% |
| Deferred Tax Liabilities, Prepaid Expenses | $707 jt2025-12-31 | $611 jt | +15,7% | $707 jt | $611 jt | +15,7% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $907 jt2025-12-31 | $558 jt | +62,5% | $907 jt | $558 jt | +62,5% |
| Deferred Tax Liabilities, Undistributed Foreign Earnings | $1,29 M2025-12-31 | $773 jt | +67,0% | $1,29 M | $773 jt | +67,0% |
| Defined Benefit Plan, Benefit Obligation, Period Increase (Decrease) | – | – | – | $898 jt | -$930 jt | +196,6% |
| Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation | $2,36 M2025-12-31 | $2,3 M | +2,7% | $2,36 M | $2,3 M | +2,7% |
| Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets | $1,06 M2025-12-31 | $1,06 M | +0,3% | $1,06 M | $1,06 M | +0,3% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, estimasi: Financial Modeling Prep. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data per 2026-11-01